Lumryz Kit
NDC Package 13551-005-01
Package Information
Lumryz (sodium oxybate) kits is a medication used to treat narcolepsy, a condition that causes severe daytime sleepiness. This formulation utilizes a kit delivery system. Marketed by Avadel Cns Pharmaceuticals, Llc, this product is identified by NDC 13551-005 and is authorized under FDA application NDA214755.
Identification & Billing
- RxCUI: 2636822 - sodium oxybate 4.5 GM Granules for extended release Oral Suspension
- RxCUI: 2636822 - sodium oxybate 4500 MG Granules for Oral Suspension
- RxCUI: 2636822 - sodium oxybate 4.5 GM (equivalent to 3.7 GM oxybate) Granules for Oral Suspension
- RxCUI: 2636828 - Lumryz 4.5 GM Granules for extended release Oral Suspension
- RxCUI: 2636828 - sodium oxybate 4500 MG Granules for Oral Suspension [Lumryz]
Clinical Specifications
Regulatory & Marketing
Hierarchy Structure
- 13551 - Avadel Cns Pharmaceuticals, Llc
- 13551-005 - Lumryz
- 13551-005-01 - 1 KIT in 1 CARTON * 1 FOR SUSPENSION, EXTENDED RELEASE in 1 PACKET * 1 FOR SUSPENSION, EXTENDED RELEASE in 1 PACKET * 1 FOR SUSPENSION, EXTENDED RELEASE in 1 PACKET
- 13551-005 - Lumryz
The NDC Directory contains ONLY information on final marketed drugs submitted to FDA electronically by labelers. A labeler might be a manufacturer, re-packager or re-labeler. The product information included in the NDC directory does not indicate that FDA has verified the information provided by the product labeler. Assigned NDC numbers are not in any way an indication of FDA approval of the product.
* Please review the full disclaimer at the bottom of this page.
Frequently Asked Questions
What is the distribution configuration for this product package?
The code 13551-005-01 identifies a specific commercial package of 1 kit in 1 carton * 1 for suspension, extended release in 1 packet * 1 for suspension, extended release in 1 packet * 1 for suspension, extended release in 1 packet of Lumryz, a human prescription drug labeled by Avadel Cns Pharmaceuticals, Llc. This kit is formulated for use and contains as the active substance.
Is this product currently listed with the FDA?
Yes, this product is active and verified within the NDC Directory. It was introduced to the market by Avadel Cns Pharmaceuticals, Llc on October 07, 2024. The current certification is valid through December 31, 2026.
What are the primary indications for this medication?
This medication is used to treat narcolepsy, a condition that causes severe daytime sleepiness. Sodium oxybate can decrease daytime sleepiness and also reduce the number of sudden short attacks of weak/paralyzed muscles (known as cataplexy) that can occur in patients with narcolepsy. Sodium oxybate is a central nervous system depressant. It is also known as gamma hydroxybutyrate (GHB).
How is this Avadel Cns Pharmaceuticals, Llc product billed for insurance claims?
For medical billing and reimbursement, this package follows the 11-digit CMS format: 13551000501. Quantities are measured in per "each", products billed on a per each basis are usually products dispensed in discreet units.. The table below illustrates the segment conversion from the 10-digit labeler code to the 11-digit provider format.
11-Digit Code Conversion
Billing payers usually require a 5-4-2 segment configuration. Below is the conversion from the 10-digit package format to the 11-digit billing format:
Note: The zero is added to the Product segment to maintain the 5-4-2 structure.